Sürdürülebilir Kalkınma Amaçları
Yayınlar
- MakaleAçık Erişim2025Does Lrig1 expression have a relationship with ERBB1 and ERBB2 expression in schizophrenia?
Uzunçakmak, Sevgi Karabulut; Özcan, Halil; Aydin, Pelin; Halici, Zekai
Purpose: This study aims to investigate Lrig1 expression and to reveal the possible relationship between Lrig1, ERBB1 and ERBB2 in schizophrenia. Materials and Methods: In this study, peripheral blood samples of 70 schizophrenia patients and 60 healthy controls were used. Real Time PCR was applied for Lrig1, ERBB1 and ERBB2 gene expression analysis. Results: The level of Lrig1 mRNA was lower in the patients when compared to healthy controls. Expression levels of ERBB1 and ERBB2 were decreased in the patients versus in the healthy controls. According to the receiver operating characteristic curve analysis, the three genes had the power to discriminate the patients from the ERBB1 and ERBB2 expressions in the patients. in schizophrenia.
- MakaleAçık Erişim2023LRIG1 levels in chronic rhinosinusitis with nasal polyps
Uzunçakmak, Sevgi Karabulut; Sahin, Abdulkadir; Özçelik, Aysegul Tavaci; Halici, Zekai
Purpose: Nasal polyps (NPs), usually occurring together with chronic rhinosinusitis (CRS), are benign masses of mucosal origin arising from inflammation. The transmembrane protein known as leucine-rich repeats and immunoglobulin-like domains 1 (Lrig1) is a member of the Lrig family. Lrig1 is frequently expressed in the respiratory tract and epithelial tissues and can inhibit several signaling pathways involved in cell proliferation. The aim of this study was to determine Lrig1 levels in NP tissues of patients with CRS. Material and Methods: This study included 36 patients with CRS and NPs and 15 patients who underwent rhinoplasty as the control group. The Lrig1 levels of all participants were measured by the ELISA method.Results: This study revealed that Lrig1 levels were significantly lower in NP tissues than in tissues of the control group. The mean level of Lrig1 of the NP tissues was 22.2 ng/ml, while the mean level of the control group was 28.5 ng/ml. According to the results of ROC analysis, Lrig1 levels have the power to distinguish polyp tissues from control tissues (AUC=0.794). Lrig1 levels were higher in tissues with scores of 4-8 than in tissues with scores of 16-20 based on the results of computed tomography scoring. According to endoscopic evaluations, Lrig1 levels of tissues with scores of 5-8 or 9-11 were relatively lower than those of tissues with scores of 2-4.Conclusion: Lrig1 levels were found to be decreased in NP tissues. Thus, Lrig1 may be used to confirm the presence of NPs. Lrig1 may also be helpful in NP grading. Increasing the Lrig1 levels in cases of NPs has the potential to become a targetable treatment modality.
AtıfWoS1OpenAlex1TR Dizin1
İncele - MakaleYalnız künye2023Scopus SJRQ2The melatonin agonist ramelteon attenuates bleomycin-induced lung fibrosis by suppressing the NLRP3/TGF-Β1/HMGB1 signaling pathway
Aydin, Pelin; Aksakalli-Magden, Zeynep B.; Civelek, Maide S.; Karabulut-Uzuncakmak, Sevgi; Mokhtare, Behzad; Ozkaraca, Mustafa; Alper, Fatih; Halici, Zekai
Purpose: The possible effects of ramelteon, a melatonin receptor agonist on bleomycin-induced lung fibrosis were analyzed via transforming growth factor β1 (TGF-β1), the high mobility group box 1 (HMGB1) and Nod-like receptor pyrin domain-containing 3 (NLRP3) which are related to the fibrosis process. Materials and methods: Bleomycin (0.1 mL of 5 mg/kg) was administered by intratracheal instillation to induce pulmonary fibrosis (PF). Starting 24 h after bleomycin administration, a single dose of ramelteon was administered by oral gavage to the healthy groups, i.e. PF + RM2 (pulmonary fibrosis model with bleomycin + ramelteon at 2 mg/kg) and PF + RM4 (pulmonary fibrosis model with bleomycin + ramelteon at 4 mg/kg) at 2 and 4 mg/kg doses, respectively. Real-time polymerase chain reaction (real-time PCR) analyses, histopathological, and immunohistochemical staining were performed on lung tissues. Lung tomography images of the rats were also examined. Results: The levels of TGF-β1, HMGB1, NLRP3, and interleukin 1 beta (IL-1β) mRNA expressions increased as a result of PF and subsequently decreased with both ramelteon doses (p < 0.0001). Both doses of ramelteon partially ameliorated the reduction in the peribronchovascular thickening, ground-glass appearances, and reticulations, and the loss of lung volume. Conclusions: The severity of fibrosis decreased with ramelteon application. These effects of ramelteon may be associated with NLRP3 inflammation cascade.
AtıfScopus9WoS9OpenAlex8
İncele